S

Solventum

Global healthcare company: wound care, dental

Third-Party Risk Analyst

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Bengaluru, Karnataka, India
HybridHybrid; travel may include up to 20%.
CybersecuritySecurity Governance, Risk & Compliance

About the job

Requirements
  • A bachelor's degree in computer science, information security, or equivalent, and seven years of relevant experience in information security or risk; alternatively, three years of direct experience in third-party risk management with a large matrixed firm.
  • An applicable certification in risk (CRISC), security (CISSP or CISM), or audit (CISA).
Responsibilities
  • Manage multiple concurrent risk assessments for Solventum systems and products, coordinating with Architecture, Vulnerability Management, Sourcing, Legal, Procurement, Product Teams, and Business Teams.
  • Perform security risk analyses and compliance assessments of third parties in accordance with industry best practices, delivering comprehensive, contextualized, and actionable information.
  • Maintain the enterprise third-party inventory by ensuring data accuracy, completeness, and integrity; monitor and report on key inventory metrics and dashboards to support effective third-party risk management and governance activities.
  • Develop strong working relationships with Sourcing, Procurement, Legal, Privacy, and other key stakeholders while maintaining a process-owner-focused approach.
  • Build and leverage an extensive network of positive relationships across Solventum and its technology organizations to support the broad requirements of the role.
  • Work independently with limited direction and guidance while effectively managing priorities.
  • Understand complex enterprise vendor use cases and identify risks associated with authentication, data management, integrations, and other key security considerations.
  • Provide risk-based recommendations and insights to support informed business decisions and strengthen third-party risk management practices.
Desired Qualifications
  • Five years of direct experience in third-party risk assessment in a private, public, government, or military environment.
  • Experience working with third-party risk management and governance applications such as OneTrust, ServiceNow, Security Scorecard, RiskRecon, or similar platforms used for inventory management, risk assessments, monitoring, and reporting.
  • Experience and proficiency working with data analytics tools used to evaluate and manage inventory, such as Tableau or Power BI.

About the company

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Eagan, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management raised EPS guidance to $7.10-$7.20.
  • Solventum announced HIS separation on August 5, 2026, sharpening its MedTech focus.
  • The $200 million Eagan Innovation Hub supports roughly 20 launches over two years.

What critics are saying

  • Management expects HIS separation to cut margins about 400 basis points after offsets.
  • ERP cutover orders distorted Q2 2026; Q3 growth resets when demand normalizes.
  • Legal costs, restructuring, and separation complexity keep Solventum exposed until 2027-2028 transactions close.

What makes Solventum unique

  • Solventum combines MedSurg, Dental, and clinical workflow assets from 3M’s healthcare spinout.
  • Its 2026 Eagan Innovation Hub concentrates wound care, sterilization, and digital health R&D.
  • The company still sells into over 75% of U.S. hospitals through entrenched workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

6%

1 year growth

6%

2 year growth

9%
PR Newswire
Oct 19th, 2026
Solventum wins FDA clearance to combine Restrata Matrix with V.A.C. Therapy for wound healing

Solventum has received US Food and Drug Administration (FDA) 510(k) clearance to use Restrata Synthetic Electrospun Fiber Matrix together with its V.A.C. Therapy, the company announced on October 19, 2026. The clearance follows Solventum's acquisition of Acera Surgical in December 2025. Restrata is a fully synthetic, resorbable matrix that supports soft tissue repair, while V.A.C. Therapy applies negative pressure to promote wound healing. Solventum says the matrix resists enzymatic degradation and matches the dressing's wear time of up to seven days. Many collagen-based dressings degrade too early for such use. The pairing may mean fewer dressing changes and a more predictable workflow for care teams. "We're giving clinicians an effective way to streamline care and support better patient outcomes," said Kelley Moffett, president of Advanced Wound Care at Solventum.

Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.